

RECEIVED

OCT 01 2002

TECH CENTER 1600/2000

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Express Mail No. EV196263777US

Sheet 1 of 1

ATTORNEY DOCKET No.

SERIAL No.

00367/1

09/897,801

APPLICANT

Pinkerton, Thomas C.

FILING DATE

GROUP

June 29, 2001

1615

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	CA	5,527,288	06/18/1996	Gross et al.	604/140	01/18/1994
2.		5,848,991	12/15/1998	Gross et al.	604/140	04/25/1997
3.		5,997,501	12/07/1999	Gross et al.	604/65	11/17/1994
4.		US2002/0038111	03/28/2002	Alchas et al.	604/500	04/13/2001
5.		US2002/0045858	04/18/2002	Alchas et al.	604/198	04/13/2001
6.		US2002/0068909	06/06/2002	Alchas et al.	604/117	04/13/2001
7.	CA	US2002/0095134	07/18/2002	Pettis et al.	604/506	06/29/2001

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
8.	CA	WO 02/02178	01/10/2002	PCT WIPO	A61M 37/00		
9.		WO 02/02179	01/10/2002	PCT WIPO	A61M 37/00		
10.	CA	EP1092444A1	04/18/2001	Europe EPD	A61M 5/46		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
11.	CA	Autret, et al.; <i>Comparison of the plasma concentration and safety of a single dose of human calcitonin following intradermal and subcutaneous administration</i> ; <u>Therapie</u> ; 46:5-8; (1991) (original and translation)
12.	CA	Bressolle et al.; <i>A wellbull distribution model for intradermal administration of ceftazidime</i> ; <u>Journal of Pharmaceutical Sciences</u> ; 82:1175-1178, (1993)

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.